San Diego-centered Viking Therapeutics marked alone as a serious competitor while in the weight loss drug sector in February soon after revealing promising data from the mid-stage demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when provided being a weekly injection and in March the company unvei